Last updated 22 days ago

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

465 patients around the world

Available in Brazil, Argentina, United States, Mexico

Eli Lilly and Company

22Research sites

465Patients around the world

This study is for people with

Diabetes

Diabetes mellitus type 1

Obesity

From 18 Years

All Gender

: Have type 1 diabetes and on insulin treatment for at least one year prior to screening.
Have an HbA1c value of 7.0% to 10.5% inclusive, at screening.
Have a body mass index (BMI) of ≥25 kilograms per square meter (kg/m2) at screening.
Are of stable weight for at least 90 days prior to screening and agree to not start an intensive diet or exercise program during the study.

: Have experienced two or more events requiring hospitalization due to poor glucose control (hyperglycemia or diabetic ketoacidosis (DKA)) during the period of 180 days prior to screening and until randomization.
Have experienced one or more events of severe hypoglycemia during the period of 90 days prior to screening and until randomization.
Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema.
Have had chronic or acute pancreatitis.
Have used any weight loss drugs or alternative remedies, including herbal or nutritional supplements, within 90 days prior to screening.

STAT Research - CABA

Av. Callao 875, CABA, Buenos Aires

Centro de Investigaciones Clínicas Baigorria

Recruiting

L. Paganini 324, S2152 Granadero Baigorria, Santa Fe, Argentina

Instituto de Investigaciones Clínicas Tucumán

Monteagudo 524, San Miguel de Tucumán

Instituto Medico Catamarca "IMEC"

Catamarca 2031, Rosario, Santa Fe

CIPADI - Centro Integral de Prevención y Atención en Diabetes

25 de mayo 1744, Mendoza

Centro Diabetológico Córdoba Dr. Waitman

Av. Velez Sarsfield 576, Córdoba

Buenos Aires Mácula S.A.

ARENALES 981, Piso:4 / 1061, CIUDAD AUTONOMA BUENOS AIRES

Mautalen - Salud e Investigación - CABA

Azcuénaga 1860 piso 8, C1128AAF Cdad. Autónoma de Buenos Aires, Argentina

Instituto da Criança com Diabetes - Cristo Redentor, Porto Alegre, Rio Grande do Sul

Rua Alvares Cabral 529, Cristo Redentor, Porto Alegre

Centro Paulista de Investigação Clínica - CEPIC

R. Moreira e Costa, 342 - Ipiranga, São Paulo - SP, 04266-010

StudySURPASS-T1D-2

SponsorEli Lilly and Company

Study typeInterventional

Conditions

Diabetes mellitus type 1Obesity

Requirements

From 18 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT06962280